Drugs / ASP1893
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06681870 | Dec 2024 → Mar 2029 | endometrial cancer, metastatic malignant neoplasm, non-small cell lung carcinoma, ovarian cancer +1 | Astellas Pharma Global Development, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP1893 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06681870 ↗ |
| Route | Intravenous | “In both parts of the study, ASP1893 will be given to people slowly through a tube into a vein.” NCT06681870 ↗ |
| Target | CLDN6 | “ASP1893, the study treatment in this study is thought to bind to CLDN6 and a protein found on certain immune cells.” NCT06681870 ↗ |